Would you treat with AZA + venetoclax to achieve CR2 before proceeding to allogeneic stem cell transplant in a young, fit patient with favorable risk AML who relapsed within a year after 7+3 and HIDAC consolidation?

Topics: Hematologic Malignancies • Pediatric Oncology • Medical Oncology • Leukemia • AML • Hematology

NGS results are pending

Answer from: Medical Oncologist at Community Practice

It would be important to know what type of "favorable risk" AML the patients had and also what the current NGS shows. I would wait on NGS results to return to see what the options are first in targeted therapies a potential option. If the patient had Core Binding Factor (CBF) AML, a high dose cytara...

Related Questions